Now You Have the Power to Save Lives from Cancer
Empower your healthcare practice with cutting-edge technology that detects cancer at its earliest, most treatable stages.
DNA ploidy testing and fluorescence visualization bring unprecedented accuracy and objectivity to cancer screening—giving you the power to intervene before cancer progresses.
Preventing cervical cancer
Cervical cancer is a leading cause of death among women in India, with one woman dying every 7 minutes.
Current screening methods are limited by subjectivity, low sensitivity, and poor specificity.
DNA ploidy testing provides 98% sensitivity and 100% specificity, enabling detection of precancerous changes up to two years earlier than conventional methods.
Non-invasive, brush-based sample collection increases patient compliance and comfort
Preventing
oral cancer
Oral cancer is the third most common cancer in men in India, with high incidence and late-stage diagnosis.
DNA ploidy testing and VELscope Vx fluorescence visualization enable early detection of lesions invisible to the naked eye.
Early intervention can prevent progression and save lives.
No organized public screening programs exist, and awareness is low.
Drastically Reduce Oral Cancer Recurrence
Traditional surgery often misses malignant tissue at the margins, leading to high recurrence rates.
PRECISION SURGERY WITH VELSCOPE Vx:
VELscope Vx guides surgeons to precisely identify and remove all abnormal tissue, reducing recurrence rates by up to 90%.
DNA ploidy testing ensures no malignant cells are left behind, providing objective, quantitative data for treatment planning.
Eliminate biopsy errors
Under white light, biopsy sites can be difficult to pinpoint, leading to sampling errors and missed diagnoses.
VELscope Vx highlights abnormal tissue beneath the mucosa, guiding accurate biopsy site selection and eliminating sampling errors.
This reduces discordance rates and ensures reliable results.
Revolutionize Oral and Cervical Cancer Survivor Follow-Up and Surveillance
Oral Cancer Solutions
Current Solution
Recurrence is difficult to detect and often delayed –Patients often return with late-stage recurrence affecting the quality of life.
Relies on patient-reported symptoms – Many patients seek care only when recurrence is severe, leading to expensive and extensive treatments.
Our Solution
Early detection of recurrence through routine TFV and DNA Ploidy check-ups helps minimize the need for extensive treatment.
Improved patient compliance – Non-invasive, quick, and reliable for post-treatment monitoring with high compliance rate.
Benefits
Lower Recurrence Costs & Improved Survival – Early intervention cuts retreatment expenses and prevents disease progression.
Sustainable & Cost-Effective Care – Lowers long-term treatment costs and avoids unnecessary hospitalizations.
Cervical Cancer Solutions
Current Solution
Recurrence is difficult to detect and often delayed –Patients often return with late-stage recurrence affecting the quality of life.
Relies on patient-reported symptoms – Many patients seek care only when recurrence is severe, leading to expensive and extensive treatments.
Our Solution
DNA Ploidy routine check-ups – Ensures early detection of recurrent lesions, reducing the need for extensive treatment.
Improved patient compliance – Non-invasive, quick, and reliable for post-treatment monitoring with high compliance rate.
Benefits
Lower Recurrence Costs & Improved Survival – Early intervention cuts retreatment expenses and prevents disease progression.
Sustainable & Cost-Effective Care – Lowers long-term treatment costs and avoids unnecessary hospitalizations.
Transform Your Lab into the Digital Pathology Era
Digitize your pathology workflow with advanced whole-slide imaging scanners and AI-powered analysis.
Enable remote consultations, large-scale diagnostic workflows, and research collaborations.
Vertically integrated manufacturing and ISO certifications guarantee quality and reliability.
DNA Ploidy Test—
Learn How It Works
Sample Collection:
Brush biopsy collects cells non-invasively.
Automated Analysis:
AI measures DNA content and assigns a DNA Index.
Feulgen Staining:
Cells are stained to highlight DNA.
Objective Results:
Abnormal (aneuploid) cells are flagged for review.
Whole Slide Imaging:
High-resolution scanning captures every cell.
Objective Results:
Abnormal (aneuploid) cells are flagged for review.
Improve Biopsy Results with Quantitative
DNA Data
RECOMMENDATION
Routine Screening is Recommended
Repeat DNA Ploidy test in 6 months. Continue patient observation until no abnormal cells are detected.
Repeat DNA Ploidy test in 6 months. Continue patient observation until no abnormal cells are detected.
Biopsy is recommended to confirm malignancy and assess cancer grade and stage.
Biopsy is recommended to confirm malignancy and assess cancer grade and stage.
DNA PLOIDY DIAGNOSIS
No cells with abnormal DNA amount detected.
1-2 cells with abnormal DNA amount (DI > 2.5) detected.
5-10% of total cells scanned are cycling
(DI = 1.25-2.5).
≥3 cells with abnormal DNA amount (DI > 2.5) detected.
>10% of total cells scanned are cycling (DI = 1.25-2.5).
DNA Index of above 2.5 are abnormal (aneuploid cells)
DNA Index of between 1.25 – 2.5 are cycling cells.
DNA Index of 1 – 1.25 are normal cells
Every cell is available for pathologist review, enabling cross-verification of software findings.
Suspicious cells are flagged with green arrows, simplifying evaluation and ensuring accuracy with 98% sensitivity and 100% specificity.
Community Screening for Cancer Is Now Affordable
Brush-based DNA ploidy testing is non-invasive, painless, and widely accepted by patients.
Automation reduces manpower needs and costs, making large-scale screening feasible.
Affordable, high-throughput solutions enable community-wide early detection programs.
Eliminate LBC PAP False Negatives
Solve HPV DNA False Negatives
HPV DNA testing has limitations in specificity and cannot predict cancer progression
Combining HPV DNA testing with DNA ploidy improves overall detection and reduces false negatives
DNA ploidy testing identifies molecular changes indicative of malignancy, providing a more reliable biomarker for cancer risk.